[HTML][HTML] Obesity-induced changes in human islet G protein-coupled receptor expression: Implications for metabolic regulation
P Atanes, T Ashik, SJ Persaud - Pharmacology & Therapeutics, 2021 - Elsevier
G protein-coupled receptors (GPCRs) are a large family of cell surface receptors that are the
targets for many different classes of pharmacotherapy. The islets of Langerhans are central …
targets for many different classes of pharmacotherapy. The islets of Langerhans are central …
Suitability and usefulness of a flexible dosing timing of oral semaglutide to maximize benefit in clinical practice: an expert panel
R Candido, C Di Loreto, P Desenzani, P Pantanetti… - Diabetes Therapy, 2024 - Springer
From clinical trials and observational data, oral semaglutide has proven to be the most
effective second-line oral therapy for the management of patients with type 2 diabetes. This …
effective second-line oral therapy for the management of patients with type 2 diabetes. This …
Retrospective analysis of the effectiveness of oral semaglutide in type 2 diabetes mellitus and its effect on cardiometabolic parameters in Japanese clinical settings
H Yamada, M Yoshida, S Funazaki, J Morimoto… - Journal of …, 2023 - mdpi.com
Glucagon-like peptide-1 receptor agonists (GLP-1RA) have a more potent glycated
hemoglobin (HbA1c)-lowering effect than existing therapies and are widely used for treating …
hemoglobin (HbA1c)-lowering effect than existing therapies and are widely used for treating …
Pain relief and pain intensity response to GLP-1 receptor agonist ROSE-010 in irritable bowel syndrome; clinical study cross-analysis with respect to patient …
AA Touny, E Kenny, M Månsson, DL Webb… - Scandinavian Journal …, 2022 - Taylor & Francis
Background and aims Glucagon-like peptide-1 receptor agonist ROSE-010 has been
studied for management of irritable bowel syndrome (IBS). ROSE-010 showed promising …
studied for management of irritable bowel syndrome (IBS). ROSE-010 showed promising …
Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy
H Ren, S Berry, SJP Malkin, B Hunt, S Bain - BMJ open, 2023 - bmjopen.bmj.com
Objectives Many people with type 2 diabetes experience clinical inertia, remaining in poor
glycaemic control on oral glucose-lowering medications rather than intensifying treatment …
glycaemic control on oral glucose-lowering medications rather than intensifying treatment …
Efficacy and Safety of Escalating the Dose of Oral Semaglutide from 7 to 14 mg: A Single-Center, Retrospective Observational Study
G Sato, H Uchino, T Hirose - Diabetes Therapy, 2024 - Springer
Introduction The efficacy and safety of oral semaglutide, the first glucagon-like peptide 1
receptor agonist available in tablet form for the treatment of type 2 diabetes, were …
receptor agonist available in tablet form for the treatment of type 2 diabetes, were …
[HTML][HTML] Пероральный семаглутид-новая¬ инновационная опция в терапии сахарного диабета 2 типа
МВ Шестакова, МШ Шамхалова, ГР Галстян… - Сахарный …, 2021 - cyberleninka.ru
Пероральный семаглутид-первый в классе агонистов рецепторов глюкагоноподобного
пептида-1, доступный в форме для приема внутрь. В рамках клинической программы …
пептида-1, доступный в форме для приема внутрь. В рамках клинической программы …
Effectiveness for adding or switching from other incretin‐related drugs to oral semaglutide in type 2 diabetes
J Oya, M Shimizu, R Kubota, R Suda… - Journal of Diabetes …, 2024 - Wiley Online Library
ABSTRACT Aims/Introduction This study aimed to evaluate and compare the effectiveness
of oral semaglutide after adding to or switching from incretin‐related drugs by assessing the …
of oral semaglutide after adding to or switching from incretin‐related drugs by assessing the …
Oral semaglutide: the innovation in type 2 diabetes management
MV Shestakova, MS Shamkhalova… - Diabetes …, 2021 - dia-endojournals.ru
Oral semaglutide is the first-in-class glucagon-like peptide-1 receptor agonist available in
the form of pills administered per os. PIONEER—the clinical trial program assessing the …
the form of pills administered per os. PIONEER—the clinical trial program assessing the …
Effect of Swallow Balloon Therapy with the Combination of Semaglutide Oral Formulation: a Randomised Double-Blind Single-Centre Study
Background Obesity is a significant public health issue; new therapies and pharmaceutical
approaches to weight management are needed. Objective This study assesses weight …
approaches to weight management are needed. Objective This study assesses weight …